CNBX Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CNBX Over the counter 8731 https://cannabics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for CNBX Pharmaceuticals Inc

CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma - Nov 8th, 2022 2:00 pm
CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy - Oct 18th, 2022 1:10 pm
CNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and Israel - Oct 13th, 2022 12:55 pm
CNBX Peer-reviewed Study: "Possible Future Therapeutic Value" for CNBX Proprietary Drug Candidate - Sep 29th, 2022 1:10 pm
CNBX Pharmaceuticals Announces New Patent Granted in Australia - Sep 28th, 2022 1:26 pm
CNBX Pharmaceuticals Granted Patent in Hong Kong - May 5th, 2022 1:11 pm